Roche (OTCMKTS:RHHBY) Shares Cross Below 50 Day Moving Average - Here's What Happened

Key Points

• Roche shares fell below their 50-day moving average, trading as low as $51.83 compared with the $55.11 average, before last trading at $52.25 on volume of 640,963 shares.
• Analyst sentiment remains generally positive: Roche has an average rating of “Moderate Buy” and an average price target of $60, with Morgan Stanley rating it overweight and assigning a $63 target.
• Roche’s financial profile includes a 1.23 current ratio, 0.95 quick ratio and 0.69 debt-to-equity ratio; several institutional investors also modestly increased their holdings.

Roche Holding AG (OTCMKTS:RHHBY - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $55.11 and traded as low as $51.83. Roche shares last traded at $52.25, with a volume of 640,963 shares trading hands.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. HSBC restated a "hold" rating on shares of Roche in a report on Thursday, September 10th. Zacks Research upgraded shares of Roche from a "strong sell" rating to a "hold" rating in a research report on Monday, August 24th. Royal Bank Of Canada assumed coverage on shares of Roche in a research note on Tuesday, September 8th. They issued an "outperform" rating on the stock. Finally, Morgan Stanley upgraded Roche from an "equal weight" rating to an "overweight" rating and set a $63.00 price target on the stock in a report on Friday, August 7th. Six analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $60.00.

Roche Price Performance

The company has a quick ratio of 0.95, a current ratio of 1.23 and a debt-to-equity ratio of 0.69. The firm has a fifty day simple moving average of $55.11 and a two-hundred day simple moving average of $52.39.

Institutional Trading of Roche

Several institutional investors have recently bought and sold shares of the business. Confluence Investment Management LLC lifted its stake in shares of Roche by 1.2% in the second quarter. Confluence Investment Management LLC now owns 20,925 shares of the company's stock worth $1,074,000 after buying an additional 258 shares in the last quarter. Enterprise Financial Services Corp grew its stake in Roche by 6.6% during the 1st quarter. Enterprise Financial Services Corp now owns 5,576 shares of the company's stock valued at $277,000 after acquiring an additional 345 shares in the last quarter. Archer Investment Corp raised its holdings in Roche by 7.7% in the 1st quarter. Archer Investment Corp now owns 5,598 shares of the company's stock valued at $278,000 after acquiring an additional 398 shares during the last quarter. Diversified Trust Co raised its holdings in Roche by 0.8% in the 1st quarter. Diversified Trust Co now owns 59,375 shares of the company's stock valued at $2,907,000 after acquiring an additional 448 shares during the last quarter. Finally, Fulton Bank N.A. lifted its stake in Roche by 5.1% in the 2nd quarter. Fulton Bank N.A. now owns 11,572 shares of the company's stock worth $597,000 after purchasing an additional 559 shares in the last quarter.

About Roche

Roche Holding AG is a Swiss healthcare company headquartered in Basel, Switzerland. Founded in 1896, the company operates through two core divisions: Pharmaceuticals and Diagnostics. Roche develops medicines and diagnostic technologies intended to support disease prevention, detection, diagnosis and treatment.

Roche's pharmaceutical activities focus on areas including oncology, immunology, neuroscience, ophthalmology, hematology and rare diseases. Its portfolio includes biologic and small-molecule medicines, as well as individualized healthcare approaches that use diagnostic information to help guide treatment decisions.

Through its Diagnostics division, Roche provides in vitro diagnostic systems, molecular testing, tissue-based diagnostics, diabetes-care products and laboratory solutions for healthcare providers, laboratories and patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.